Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety

References

• National Cancer Institute. Cancer stat facts: myeloma. Available from: http://seer.cancer.gov/statfacts/htlm/mulmy.htlm.
   Google Scholar
• AndersonKC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22:5419–5427.28151709
   PubMed Web of Science ®Google Scholar
• KumarSK, RajkumarSV, DispenzieriA, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.17975015
   PubMed Web of Science ®Google Scholar
• KumarSK, DispenzieriA, LacyMQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.24157580
   PubMed Web of Science ®Google Scholar
• TacchettiP, PatriarcaF, PetrucciMT, et al. A triplet bortezomib- and immunomodulator-based therapy before and after double ASCT improves overall survival of newly diagnosed MM patients: final analysis of Phase 3 GIMEMA-MMY-3006 study. Hemasphere. 2018;2(S1):abstractS105.
   Google Scholar
• NandakumarB, BinderM, DispenzieriA, et al. Continued improvement in survival in multiple myeloma, including high-risk patients. J Clin Oncol. 2019;37(suppl):abstract 8039.
   Google Scholar
• KumarSK, TherneauTM, GertzMA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867–874.15244382
   PubMed Web of Science ®Google Scholar
• GandhiUH, CornellRF, LakshmanA, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–2275.30858549
   PubMed Web of Science ®Google Scholar
• CoiffierB, ThieblemontC, Van Den NesteE, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–2045.20548096
   PubMed Web of Science ®Google Scholar
• ConnorsJM, JurczakW, StrausDJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344. doi:10.1056/NEJMoa170898429224502
   PubMed Web of Science ®Google Scholar
• OffidaniM, CorvattaL. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. Future Oncol. 2018;14:319–329.29091475
   PubMed Web of Science ®Google Scholar
• LonialS, DimopoulosMA, PalumboA, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.26035255
   PubMed Web of Science ®Google Scholar
• DimopoulosMA, DytfeldD, GrosickiS, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–1822.30403938
   PubMed Web of Science ®Google Scholar
• NookaAK, KaufmanJL, HofmeisterCC, et al. Daratumumab in multiple myeloma. Cancer. 2019;125:2364–2382.30951198
   PubMed Web of Science ®Google Scholar
• LokhorstHM, PlesnerT, LaubachJP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. New Engl J Med. 2015;373:1207–1219.26308596
   PubMed Web of Science ®Google Scholar
• LonialS, WeissBM, UsmaniSZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.26778538
   PubMed Web of Science ®Google Scholar
• DimopoulosMA, OriolA, NahiH, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New Engl J Med. 2016;375:1319–1331.27705267
   PubMed Web of Science ®Google Scholar
• PalumboA, Chanan-KhanA, WeiselK, et al. Daratumumab, Bortezomib, and dexamethasone for multiple myeloma. New Engl J Med. 2016;375:754–766.27557302
   PubMed Web of Science ®Google Scholar
• DimopoulosMA, TerposE, BoccadoroM, et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):abstract 412.
   Google Scholar
• DimopoulosM, QuachH, MateosM-V, et al. Carfilzomib, dexamethasone, and daratumumab versus Carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomized, multicenter, open-label, phase 3 trial. Lancet. 2020;396:186–197.32682484
   PubMed Web of Science ®Google Scholar
• MoreauP, AttalM, HulinC, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CSSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.31171419
   PubMed Web of Science ®Google Scholar
• MateosMV, DimopoulosMA, CavoM, et al. Daratumumab plus Bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–528.29231133
   PubMed Web of Science ®Google Scholar
• FaconT, KumarS, PlesnerT, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma (MAIA). N Engl J Med. 2019;380:2104–2105.31141632
   PubMed Web of Science ®Google Scholar
• FengX, ZhangL, AcharyaC, et al. Targeting CD38 suppresses induction and function of t regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290–4300.28249894
   PubMed Web of Science ®Google Scholar
• AttalM, RichardsonPG, RajkumarSV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096–2107.31735560
   PubMed Web of Science ®Google Scholar
• GravinaGL, SenapedisW, McCauleyD, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85.25476752
   PubMed Web of Science ®Google Scholar
• GrosickiS, SimonovaM, SpickaI, et al. Once-per-week selinexor, Bortezomib, and dexamethasone versus twice-per-week Bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomized, open-label, phase 3 trial. Lancet. 2020;396:1563–1573.33189178
   PubMed Web of Science ®Google Scholar
• ChariA, VoglDT, GavriatopoulouM, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727–738.31433920
   PubMed Web of Science ®Google Scholar
• ChauhanD, RayA, ViktorssonK, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19:3019–3031.23584492
   PubMed Web of Science ®Google Scholar
• RichardsonPG, OriolA, LaroccaA, et al. HORIZON (OP-106): melflufen plus dexamethasone in relapsed/refractory multiple myeloma refractory to pomalidomide and/or anti-CD38 monoclonal antibody-primary and subgroup analysis. Hemasphere. 2020;4(S1):abstract EP 945.
   Google Scholar
• BjorklundCC, KangJ, AmatangeloM, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34:1197–1201.31719682
   PubMed Web of Science ®Google Scholar
• KumarSK, HarrisonSJ, CavoM, et al. Venetoclax or placebo in combination with Bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomized, double-blind, multicenter, phase 3 trial. Lancet Oncol. 2020;21:1630–1642.33129376
   PubMed Web of Science ®Google Scholar
• LancmanG, RichterJ, ChariA. Bispecific, trispecific, and other novel immune treatments in myeloma. Hematology. 2020;264–271.
   Web of Science ®Google Scholar
• MikkilinemiL, KochenderferJN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130:2594–2602.28928126
   PubMed Web of Science ®Google Scholar
• MunshiNC, AndersonLD, ShaN, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–716.33626253
   PubMed Web of Science ®Google Scholar
• GarfallAL, UsmaniSZ, MateosM-V, et al. Updatedp Phase 1 results of teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl 1):abstract 27.
   Web of Science ®Google Scholar
• TaiYT, AndersonKC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011:924058.22046572
   PubMedGoogle Scholar
• TamuraH. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278–285.29368256
   PubMed Web of Science ®Google Scholar
• NeriP, AlbergeJ-B, MaityR, et al. Expansion of effector memory CD27+T cells and tolerogenic type 2 classical dendritic cells regulate myeloma patients’ sensitivity to daratumumab and IMiDS. Clin Lymph Myeloma Leuk. 2019;19:e29–e30.
   Web of Science ®Google Scholar
• NahiH, ChrobokM, GranC, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PloSOne. 2019;14:e0211927.
   PubMed Web of Science ®Google Scholar
• TsuchikamaK, ZhiqiangA. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46.27743348
   PubMed Web of Science ®Google Scholar
• MadryC, LaabiY, CallebautI, et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. 1998;10:1693–1702.9846698
   PubMed Web of Science ®Google Scholar
• RennertP, SchneiderP, CacheroTG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000;192:1677–1683.11104810
   PubMed Web of Science ®Google Scholar
• TaiY-T, AcharyaC, AnG, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225–3236.27127303
   PubMed Web of Science ®Google Scholar
• SanchezE, LiM, KittoA, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–738.22804669
   PubMed Web of Science ®Google Scholar
• DispenzieriA, SoofCM, RajkumarV, et al. Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). J Clin Oncol. 2019;37(15 Suppl):abstract 8020.
   Google Scholar
• GhermeziM, LiM, VardanyanS, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102:785–795.28034989
   PubMed Web of Science ®Google Scholar
• TolcherAW. The evolution of antibody-drug conjugates: a positive inflexion point. Am Soc Clin Oncol Educ Book. 2020;40:1–8.
   PubMedGoogle Scholar
• LuJ, JiangF, LuA, et al. Linkers having a crucial role in antibody-drug conjugates. Int J Mol Sci. 2016;17:561.27089329
   PubMed Web of Science ®Google Scholar
• YuB, LiuD. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12:94.31500657
   PubMed Web of Science ®Google Scholar
• HerreraAF, MolinaA. Investigational antibody-drug conjugates for treatment of B-lineage malignancies. Clin Lymphoma Myeloma Leuk. 2018;18:452–468.29804872
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf): US prescribing information. 2020. https://www.accessdata.fda.gov/. Accessed 524, 2021.
   Google Scholar
• TaiYT, MayesPA, AcharyaC, et al. novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–3138.24569262
   PubMed Web of Science ®Google Scholar
• Montes de OcaR, BhattacharyaS, VitaliN, et al. The anti-BCMA antibody-drug conjugate GSK2857916 drivers immunogenic cell death and immune-mediated antitumor responses, and in combination with an OX40 agonist potentiates in vivo activity. HemaShere. 2019;3(S2):abstractPF558.
   Google Scholar
• TrudelS, LendvaiN, PopatR, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641–1653.30442502
   PubMed Web of Science ®Google Scholar
• EatonJS, MillerPE, MannisMJ, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589–604.26539624
   PubMed Web of Science ®Google Scholar
• TrudelS, LendvaiN, PopatR, et al. Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9:37.30894515
   PubMed Web of Science ®Google Scholar
• LonialS, LeeHC, BadrosA, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–221.31859245
   PubMed Web of Science ®Google Scholar
• KumarS, PaivaB, AndersonKC, et al. International Myeloma Working Cohort consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.27511158
   PubMed Web of Science ®Google Scholar
• LonialS, LeeHC, BadrosA, et al. DREAMM-2: single agent belantamab mafodotin in relapsed/refractory multiple myeloma refractory to proteasome inhibitors, immunomodulatory agents, and refractory and/or intolerant to anti-CD38 mAbs. HemaSphere. 2020;4(S1):abstract EP970.
   Google Scholar
• TzoganiK, PenttilaK, LahteenvuoJ, et al. EMA review of belantamab mafodotin (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma. Oncologist. 2021;26:70–76.33179377
   PubMed Web of Science ®Google Scholar
• NookaA, LeeHC, BadrosA, et al. Infusion-related reactions (IRRs) in the DREAMM-2 study of single-agent belantamab mafodotin (Belamaf) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract 3221.
   Google Scholar
• PopatR, LonialS, VoorheesPM, et al. DREAMM-2: single-agent belantamab mafodotin (Belamaf) effects on patient-reported outcome (PRO) measures in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract2278.
   Google Scholar
• LeeHC, CohenAD, ChariA, et al. DREAMM-2: single-agent belantamab mafodotin (GSK2857918) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. J Clin Oncol. 2020;38(Suppl):abstract 8519.
   Google Scholar
• CohenAD, TrudelS, LonialS, et al. DREAMM-2: single-agent belantamab mafodotin (GSK2857918) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk cytogenetics. HemaSphere. 2020;4(S1):abstract EP1037.
   Google Scholar
• LonialS, LeeHC, TrudelS, et al. DREAMM-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (RRMM)-1-year outcomes by prior therapies. Blood. 2020;136(Suppl. 1):abstract 1417.
   Google Scholar
• CohenAD, LeeHC, TrudelS, et al. Impact of prolonged dose delays on response with belantamab mafodotin (Belamaf; GSK2857916) treatment in the in the DREAMM-2 study: 13-month follow-up. Clin Lymphoma Myeloma Leuk. 2020;20(Suppl. 1):abstractMM250.
   Google Scholar
• MarkhamA. Belantamab Mafodotin: first approval. Drugs. 2020;80:1607–1613.32936437
   PubMed Web of Science ®Google Scholar
• Ferron-BradyG, RathiC, CollinsJ, et al. Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed/refractory multiple myeloma: application of population pharmacokinetics (PopPK) and exposure-response (E-R) analyses. Cancer Res. 2020;80(16 Suppl):abstract CT196.
   Google Scholar
• GandhiAK, KangJ, HavensCG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. Br J Haematol. 2014;164:811–821.24328678
   PubMed Web of Science ®Google Scholar
• TrudelS, McCurdyA, SutherlandHJ, et al. Part 1 results of a dose finding study of belantamab mafodotin (GSK2857916) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl. 1):abstract725.
   Google Scholar
• RichardsonPG, OriolA, BeksacM, et al. Pomalidomide, Bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781–794.31097405
   PubMed Web of Science ®Google Scholar
• ChenCI, BahlisN, GasparettoC, et al. Selinexor, pomalidomide and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(Suppl. 1):abstract141.
   Google Scholar
• NookaAK, MateosM-V, BahlisN, et al. DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. HemaSphere. 2020;4(S1):abstract EP955.
   Google Scholar
• RichardsonPG, NookaA, QuachH, et al. DREAMM-5 platform trial: belantamab mafodotin (belamaf) in combination with four different novel agents in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract2999.
   Google Scholar
• PopatR, NookaA, Stockerl-GoldsteinK, et al. DREAMM-6: safety, tolerability and clinical activity of bellantamab mafodotin (Belamaf) in combination with bortezomib/dexamethasone in relapsed/ refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract 1419.
   Google Scholar
• RifkinRM, BoydK, GrosickiS, et al. DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with Bortezomib, and dexamethasone (B-Vd) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract 3247.
   Google Scholar
• TrudelS, DavisR, LewisNM, et al. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus Bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract 2302.
   Google Scholar
• FarooqAV, Degli EspostiS, PopatR, et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 Study. Ophthalmol Ther. 2020;9:889–911.32712806
   PubMed Web of Science ®Google Scholar
• LonialS, NookaA, ThulasiP, et al. Recovery of ocular events with longer-term follow-up in the DREAMMM-2 study of single-agent belantamab mafodotin (belamaf) in patients with relapsed or refractory multiple myeloma (RRMM). Blood. 2020;136(Suppl. 1):abstract 3224.
   Google Scholar
• BecnelMR, LeeHC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2020;11:1–11.
   Web of Science ®Google Scholar
• Ferron-BradyG, RathiC, CollinsJ, et al. Exposure-response (E-R) for ocular safety endpoints for belantamab mafodotin (belamaf), a B-Cell Maturation Antigen (BCMA)-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM) in the DREAMM-2 study. Blood. 2020;136(Suppl. 1):abstract 1420.
   Google Scholar
• PopatR, WarcelD, O’NionsJ, et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020;105:e261–e263.32107339
   PubMed Web of Science ®Google Scholar
• LinH-P, SinglaB, GhoshalP, et al. Identification of novel micropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs. Br Journal of Pharmacology. 2018;175:3640–3655.
   PubMed Web of Science ®Google Scholar
• DimopoulosMA, MoreauP, TerposE, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309–322.33549387
   PubMed Web of Science ®Google Scholar